Literature DB >> 2049899

Population pharmacokinetics of lithium.

D M Jermain1, M L Crismon, E S Martin.   

Abstract

The population pharmacokinetics of lithium was determined. Psychiatric inpatients who were at least 18 years old, had normal renal function, and were receiving lithium two or three times daily were the subjects of the study; 79 patients met the criteria. Serum lithium concentrations were measured by flame photometry 12 hours after the evening dose. Other data collected included age, gender, race, height, weight, serum creatinine and sodium concentrations, diet, and concurrent drug use. The nonlinear mixed-effects model (NONMEM) program was used to estimate lithium clearance, lithium volume of distribution, and error variability and to determine the influence of patient characteristics on lithium clearance. With the initial model, the mean lithium volume of distribution was 32.8 L and mean lithium clearance was 1.36 L/hr. With an intermediate model, lithium clearance estimates improved on the basis of patient size (weight and body surface area), daily lithium dosage, age, gender, and race. When only the most significant variables--lean body weight and creatinine clearance--were retained, a final model was obtained that yielded a coefficient of variation for lithium clearance of about 24% and gave fairly accurate predictions of steady-state lithium concentrations (coefficient of variation, about 16%). Analysis of lithium pharmacokinetics with the NONMEM program suggested that lean body weight and creatinine clearance are important predictors of lithium clearance.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2049899

Source DB:  PubMed          Journal:  Clin Pharm        ISSN: 0278-2677


  14 in total

1.  First-dose pharmacokinetics of lithium carbonate in children and adolescents.

Authors:  Robert L Findling; Cornelia B Landersdorfer; Vivian Kafantaris; Mani Pavuluri; Nora K McNamara; Jon McClellan; Jean A Frazier; Linmarie Sikich; Robert Kowatch; Jacqui Lingler; Jon Faber; Perdita Taylor-Zapata; William J Jusko
Journal:  J Clin Psychopharmacol       Date:  2010-08       Impact factor: 3.153

2.  Relationships among liver and kidney volumes, lean body mass and drug clearance.

Authors:  S Nawaratne; J E Brien; E Seeman; R Fabiny; J Zalcberg; W Cosolo; P Angus; D J Morgan
Journal:  Br J Clin Pharmacol       Date:  1998-11       Impact factor: 4.335

Review 3.  Differential pharmacokinetics of lithium in elderly patients.

Authors:  B A Sproule; B G Hardy; K I Shulman
Journal:  Drugs Aging       Date:  2000-03       Impact factor: 3.923

4.  Accuracy of the Pepin method to determine appropriate lithium dosages in healthy volunteers.

Authors:  E Stip; J Dufresne; B Boulerice; R Elie
Journal:  J Psychiatry Neurosci       Date:  2001-09       Impact factor: 6.186

5.  Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis.

Authors:  J R Wade; A W Kelman; C A Howie; B Whiting
Journal:  J Pharmacokinet Biopharm       Date:  1993-04

6.  Interaction between structural, statistical, and covariate models in population pharmacokinetic analysis.

Authors:  J R Wade; S L Beal; N C Sambol
Journal:  J Pharmacokinet Biopharm       Date:  1994-04

Review 7.  Population Pharmacokinetic Analyses of Lithium: A Systematic Review.

Authors:  Janthima Methaneethorn
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-02       Impact factor: 2.441

Review 8.  What is the best size descriptor to use for pharmacokinetic studies in the obese?

Authors:  Bruce Green; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

Review 9.  Clinical relevance of drug interactions with lithium.

Authors:  P R Finley; M D Warner; C A Peabody
Journal:  Clin Pharmacokinet       Date:  1995-09       Impact factor: 6.447

Review 10.  Lean body mass as a predictor of drug dosage. Implications for drug therapy.

Authors:  D J Morgan; K M Bray
Journal:  Clin Pharmacokinet       Date:  1994-04       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.